# 2025-11791: FDA Gives X-Ray-Blocking Cream Its Own Official Device Classification

2025-11791, Medical Devices; Radiology Devices; Classification of the Cream for X-Ray Attenuation, is a Federal Register rule from Health and Human Services Department, Food and Drug Administration published 2025-06-26, effective 2025-06-26; PRIA reads it as touching household money (as of 2026-11-05).

- Canonical: https://policyrisk.com/federal-register/2025-11791
- As of: 2026-11-05
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-11791
- Title: Medical Devices; Radiology Devices; Classification of the Cream for X-Ray Attenuation
- Type: Rule
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 27236
- Published: 2025-06-26
- Effective: 2025-06-26
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-11-05

## In one line

FDA Gives X-Ray-Blocking Cream Its Own Official Device Classification

## Summary

The FDA is officially classifying the cream used to block X-rays as a Class II device with special safety rules. This change makes it easier and safer for patients to get this innovative cream by lowering regulatory hurdles. The new classification is effective June 26, 2025, and helps companies bring these creams to market faster without extra costs.

## Abstract

The Food and Drug Administration (FDA, the Agency, or we) is classifying the cream for x-ray attenuation into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for the cream for x-ray attenuation's classification. We are taking this action because we have determined that classifying the device into class II (special controls) will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.

## Effects PRIA read

- Cream classified Class II; access improved: benefit, medium. You may get faster access to this X-ray attenuation cream because the FDA officially classified it as Class II with special controls, effective June 26, 2025 (the classification was applicable May 9, 2013). The FDA says this classification reduces regulatory burdens and will enhance patients' acces…
- Device uses 510(k) pathway (not PMA): benefit, medium. The cream for X-ray attenuation is subject to premarket notification under section 510(k) rather than premarket approval, and the De Novo classification lets this device serve as a predicate for future devices. That means manufacturers can use the less burdensome 510(k) process to bring similar pro…
- Mandatory testing and labeling requirements: mixed, medium. Manufacturers must perform specific safety and performance testing (including biocompatibility, sterilization/expiration testing, glove compatibility, attenuation performance, and application testing) and include labeling such as a sterility statement and boxed warning. Labeling must also give atte…
- Use limits: up to 130 kVp; not for primary beam: benefit, low. The cream is intended as a sterile radiation shield for hands during procedures with diagnostic imaging exposure up to 130 kVp; it should be applied to the hand before donning gloves or on a glove followed by a second glove. The device must not be used in or next to the primary X-ray beam and shoul…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2025-11791 on federalregister.gov](https://www.federalregister.gov/documents/2025/06/26/2025-11791/medical-devices-radiology-devices-classification-of-the-cream-for-x-ray-attenuation)
- [2025-11791 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-06-26/pdf/2025-11791.pdf)

## Related
- [Previous: 2025-11781, Medical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classifica…](https://policyrisk.com/federal-register/2025-11781)
- [Next: 2025-11793, Medical Devices; Hematology and Pathology Devices; Classification of the Fluore…](https://policyrisk.com/federal-register/2025-11793)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-11791 (as of 2026-11-05).
